Health Care & Life Sciences » Biotechnology | Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
7,862.00
44,377.00
8,676.00
69,429.00
11,698.00
15,622
Cost of Goods Sold (COGS) incl. D&A
1,563.00
1,400.00
-
-
-
-
Gross Income
6,299.00
42,977.00
-
-
-
-
SG&A Expense
47,023.00
42,681.00
45,424.00
58,847.00
66,377.00
63,081
EBIT
40,724.00
296.00
37,313.00
8,504.00
55,800.00
48,956
Unusual Expense
2,256.00
3,074.00
1,991.00
4,600.00
2,600.00
17,400
Non Operating Income/Expense
-
-
-
34.00
247.00
21
Interest Expense
-
-
-
800.00
5,100.00
5,000
Pretax Income
42,934.00
3,421.00
39,252.00
12,577.00
62,685.00
69,289
Income Tax
362.00
989.00
133.00
1,844.00
11,672.00
1,632
Consolidated Net Income
42,572.00
4,410.00
39,119.00
10,733.00
51,013.00
67,657
Net Income
42,572.00
4,410.00
39,112.00
10,806.00
51,013.00
67,657
Net Income After Extraordinaries
42,572.00
4,410.00
39,112.00
10,806.00
51,013.00
67,657
Net Income Available to Common
42,572.00
4,410.00
39,112.00
10,806.00
51,013.00
67,657
EPS (Basic)
0.76
0.06
0.56
0.15
0.73
0.87
Basic Shares Outstanding
55,798.00
68,185.00
69,716.00
70,003.00
70,284.00
77,890
EPS (Diluted)
0.76
0.06
0.56
0.15
0.73
0.87
Diluted Shares Outstanding
55,798.00
68,243.00
69,716.00
70,155.00
70,284.00
77,890
EBITDA
39,785.00
841.00
36,748.00
10,582.00
54,679.00
47,459
Non-Operating Interest Income
46.00
51.00
52.00
307.00
1,062.00
2,088
Minority Interest Expense
-
-
7.00
73.00
-
-

About Progenics Pharmaceuticals

View Profile
Address
One World Trade Center
New York New York 1000
United States
Employees -
Website http://www.progenics.com
Updated 07/08/2019
Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.